MX2015015232A - Anticuerpo monoclonal dirigido contra cxcr5. - Google Patents
Anticuerpo monoclonal dirigido contra cxcr5.Info
- Publication number
- MX2015015232A MX2015015232A MX2015015232A MX2015015232A MX2015015232A MX 2015015232 A MX2015015232 A MX 2015015232A MX 2015015232 A MX2015015232 A MX 2015015232A MX 2015015232 A MX2015015232 A MX 2015015232A MX 2015015232 A MX2015015232 A MX 2015015232A
- Authority
- MX
- Mexico
- Prior art keywords
- monoclonal antibody
- directed against
- antibody directed
- against cxcr5
- cxcr5
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 102000049118 human CXCR5 Human genes 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención se refiere a anticuerpos monoclonales contra CXCR5 de humano, y a su uso en el tratamiento de enfermedades autoinmunes o inflamatorias, así como cánceres.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13166251 | 2013-05-02 | ||
PCT/EP2014/058903 WO2014177652A1 (en) | 2013-05-02 | 2014-04-30 | Monoclonal antibody directed against cxcr5 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015015232A true MX2015015232A (es) | 2016-02-22 |
Family
ID=48184103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015015232A MX2015015232A (es) | 2013-05-02 | 2014-04-30 | Anticuerpo monoclonal dirigido contra cxcr5. |
Country Status (14)
Country | Link |
---|---|
US (1) | US9534054B2 (es) |
EP (1) | EP2992014A1 (es) |
JP (1) | JP6522585B2 (es) |
KR (1) | KR20160003804A (es) |
CN (1) | CN105392802B (es) |
AU (1) | AU2014261398B2 (es) |
BR (1) | BR112015027388A2 (es) |
CA (1) | CA2909587A1 (es) |
HK (1) | HK1217340A1 (es) |
MX (1) | MX2015015232A (es) |
RU (1) | RU2015150723A (es) |
SG (1) | SG11201508502RA (es) |
WO (1) | WO2014177652A1 (es) |
ZA (1) | ZA201508081B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL310558A (en) * | 2016-12-21 | 2024-03-01 | Bayer Pharma AG | Drug-antibody conjugates with enzymatically cleavable groups |
FR3061716B1 (fr) * | 2017-01-06 | 2019-05-17 | Elsalys Biotech | Nouveaux composes ciblant le cd160 humain |
CA3025536A1 (en) * | 2017-12-01 | 2019-06-01 | Pfizer, Inc. | Anti-cxcr5 antibodies and compositions and uses thereof |
AU2019289506A1 (en) * | 2018-06-18 | 2021-02-04 | Bayer Aktiengesellschaft | Binder-drug conjugates directed against CXCR5, having enzymatically cleavable linkers and improved activity profile |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512701B2 (en) | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
WO2009032661A1 (en) * | 2007-08-29 | 2009-03-12 | Sanofi-Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
-
2014
- 2014-04-30 KR KR1020157033857A patent/KR20160003804A/ko not_active Application Discontinuation
- 2014-04-30 MX MX2015015232A patent/MX2015015232A/es unknown
- 2014-04-30 CA CA2909587A patent/CA2909587A1/en not_active Abandoned
- 2014-04-30 AU AU2014261398A patent/AU2014261398B2/en not_active Expired - Fee Related
- 2014-04-30 CN CN201480024907.XA patent/CN105392802B/zh not_active Expired - Fee Related
- 2014-04-30 WO PCT/EP2014/058903 patent/WO2014177652A1/en active Application Filing
- 2014-04-30 US US14/787,478 patent/US9534054B2/en not_active Expired - Fee Related
- 2014-04-30 SG SG11201508502RA patent/SG11201508502RA/en unknown
- 2014-04-30 EP EP14720970.4A patent/EP2992014A1/en not_active Withdrawn
- 2014-04-30 RU RU2015150723A patent/RU2015150723A/ru not_active Application Discontinuation
- 2014-04-30 JP JP2016511072A patent/JP6522585B2/ja not_active Expired - Fee Related
- 2014-04-30 BR BR112015027388A patent/BR112015027388A2/pt not_active IP Right Cessation
-
2015
- 2015-10-30 ZA ZA2015/08081A patent/ZA201508081B/en unknown
-
2016
- 2016-05-10 HK HK16105293.5A patent/HK1217340A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN105392802A (zh) | 2016-03-09 |
AU2014261398B2 (en) | 2019-08-29 |
AU2014261398A1 (en) | 2015-11-12 |
KR20160003804A (ko) | 2016-01-11 |
WO2014177652A1 (en) | 2014-11-06 |
EP2992014A1 (en) | 2016-03-09 |
BR112015027388A2 (pt) | 2017-08-29 |
US20160115235A1 (en) | 2016-04-28 |
CN105392802B (zh) | 2019-09-03 |
JP6522585B2 (ja) | 2019-05-29 |
JP2016524595A (ja) | 2016-08-18 |
RU2015150723A (ru) | 2017-06-07 |
US9534054B2 (en) | 2017-01-03 |
ZA201508081B (en) | 2017-09-27 |
HK1217340A1 (zh) | 2017-01-06 |
SG11201508502RA (en) | 2015-11-27 |
CA2909587A1 (en) | 2014-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
PH12015502565B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
TN2015000396A1 (en) | Antibody drug conjugates | |
MX2020002289A (es) | Anticuerpos anti-alfa-sinucleina y metodos de uso. | |
MX2015016111A (es) | Anticuerpos anti-b7-h5 y sus usos. | |
MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
MX2022007522A (es) | Anticuerpos anti-cd27. | |
PE20210648A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
MX2017007585A (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
MX353476B (es) | Anticuerpos anti-cxcl13 y metodos para usarlos. | |
GB201109238D0 (en) | Antibodies | |
MX2016005854A (es) | Anticuerpo anti-her3 alosterico de la neuregulina. | |
MX2014014381A (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
MX2015015232A (es) | Anticuerpo monoclonal dirigido contra cxcr5. | |
MX2014014443A (es) | Agentes de ligacion a tlr3. | |
EA201890489A1 (ru) | Car макрофагов (moto-car) в иммунотерапии |